Alnylam Pharmaceuticals to Showcase New Analyses at Heart Failure 2026 Highlighting the Consistent Clinical Profile of Vutrisiran in ATTR-CM Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced that it will present a comprehensive set of new data analyses for vutrisiran in patients…
Rejoni Names John Nealon as Chief Executive Officer to Lead Its Women’s Health MedTech Strategy Rejoni Inc., a privately held clinical-stage biotechnology company focused on advancing uterine health through innovative biomaterial therapies, has announced the appointment of John Nealon as…
Assertio Enters into Revised and Restated Merger Agreement with Garda Therapeutics Assertio Holdings has announced a significant update to its pending acquisition by Garda Therapeutics, revealing that the two companies have entered into an amended and restated merger agreement as…
Ironwood Presents Survey Data at DDW 2026 Highlighting Urgent Need for Treatments Addressing the Multifaceted Burden of Total Parenteral Nutrition in Short Bowel Syndrome Ironwood Pharmaceuticals, a biotechnology company focused on developing and commercializing therapies for gastrointestinal (GI) and rare…
Incyte Secures FDA Approval for Jakafi XR™ (ruxolitinib) Extended-Release Tablets Across Multiple Hematologic Indications Incyte has announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets, introducing a new once-daily treatment option for patients…
E-Scopics Secures FDA Clearance for Enhanced Hepatoscope® Featuring Advanced Elastography and Expanded Liver Disease Management Capabilities, to Be Showcased at DDW 2026 E-Scopics has announced a major advancement in its point-of-care ultrasound technology with new U.S. regulatory clearance for enhanced…
Arrowhead Pharmaceuticals Secures TGA Approval for REDEMPLO® (plozasiran) in Australia, Broadening Access for Patients with Familial Chylomicronemia Syndrome (FCS) Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has announced a significant regulatory milestone with the approval of REDEMPLO by Australia’s Therapeutic Goods Administration…
Acadia Pharmaceuticals Plans Year-End Retirement of R&D Chief Elizabeth H.Z. Thompson After Distinguished Career Acadia Pharmaceuticals Inc. has announced that Elizabeth H.Z. Thompson, Ph.D., its Head of Research and Development, plans to retire from her role for personal reasons. The…
Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Positioned to Enter CAR-T Market with 67% Complete Response Rate South Korean biotechnology company Curocell (KOSDAQ: 372320) has achieved a landmark milestone in the nation’s advanced therapeutics landscape with the full regulatory approval…
Cosette Pharmaceuticals Names Erika Tooman as Senior Vice President and General Counsel, Enhancing Leadership to Support Growth and Strategic Expansion Cosette Pharmaceuticals, a U.S.-based branded specialty pharmaceutical company, has announced the appointment of Erika Tooman as Senior Vice President and…
Strand Therapeutics Names Kunal Bhatia as Chief Financial Officer Strand Therapeutics, a clinical-stage biotechnology company focused on advancing programmable mRNA medicines, has announced the appointment of Kunal Bhatia as its new Chief Financial Officer. The move comes at a pivotal…
Masimo SET® Pulse Oximetry Demonstrates Consistent Accuracy Across All Newborn Skin Tones in Largest-Ever Real-World Prospective Study Masimo has announced new clinical findings that reinforce the accuracy and reliability of its SET® pulse oximetry technology in one of the most…